Ziopharm Oncology (ZIOP) Misses Q2 EPS Views
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Ziopharm Oncology (NASDAQ: ZIOP) reported Q2 EPS of ($1.01), $0.90 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.52 million.
For earnings history and earnings-related data on Ziopharm Oncology (ZIOP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NCI, Inc. (NCIT) Tops Q3 EPS by 1c, Offers Q4 Guidance
- Nutrisystem (NTRI) Tops Q3 EPS by 1c; Offers Guidance
- Encore Wire (WIRE) Misses Q2 EPS by 27c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!